The Journal of Herbal Medicine, published by Elsevier GmbH in Germany, stands at the forefront of research in the dynamic and evolving field of complementary and alternative medicine. With an ISSN of 2210-8033 and an E-ISSN of 2210-8041, this journal has been contributing significant insights since its inception in 2011 and continues to be a vital resource through 2024. Recognized for its scholarly rigor, it holds a commendable Q2 ranking in the 2023 Scopus category for Complementary and Alternative Medicine, placing it in the upper echelons of its field with a rank of 32 out of 105 journals, marking it in the 70th percentile. The Journal of Herbal Medicine emphasizes the integration of traditional herbal therapies and modern scientific approaches, offering researchers, professionals, and students a platform for disseminating their findings and fostering an inclusive dialogue on natural medicine's role in healthcare. Although it is not an open-access publication, its commitment to high-quality research makes it an essential read for those wanting to explore the efficacy and application of herbal medicine in contemporary practice.

The Chinese Journal of Natural Medicines, published by the esteemed CHINESE JOURNAL NATURAL MEDICINES, plays a pivotal role in the exploration and advancement of complementary and alternative medicine. With an ISSN of 2095-6975 and an E-ISSN of 1875-5364, this journal is recognized for its commitment to high-quality research and innovative findings in the realms of drug discovery and miscellaneous medical fields. Operating from China, it has earned a prestigious reputation in the academic community, achieving Q1 status in Complementary and Alternative Medicine and Q2 rankings in both Drug Discovery and Miscellaneous Medicine as of 2023, solidifying its influence within the scientific discourse. Researchers and professionals will find valuable insights here as the journal explores the intersection of traditional natural medicines with modern pharmacological science, making it an essential resource for anyone dedicated to the field. With a convergence period from 2004 to 2024, the journal continues to champion open dialogue and disseminate significant findings critical for the development of effective natural therapies.

PHARMACEUTICAL BIOLOGY, published by Taylor & Francis Ltd, is a prominent open-access journal that has been a cornerstone of research in the life sciences since its convergence in 1961. With a strong focus on Complementary and Alternative Medicine, Pharmaceutical Science, and Drug Discovery, this journal is dedicated to disseminating groundbreaking research that intersects pharmaceuticals and biology. Acknowledged for its rigorous peer-review process, it holds a prestigious Q1 ranking in Pharmaceutical Science and exemplifies the commitment to quality and impact in the field, boasting an impressive Scopus rank of #14/105 in the complementary and alternative medicine category. Researchers keen on advancing their knowledge in these fields will find PHARMACEUTICAL BIOLOGY an invaluable resource, offering accessibility since its shift to open access in 2017. This journal presents a platform for innovative studies that contribute to the evolving understanding of pharmaceutical applications and biological interactions, serving as an essential hub for researchers, professionals, and students alike.

MEDICINE, published by Lippincott Williams & Wilkins, is an esteemed open access journal in the field of general medicine, holding a significant position with a Scopus rank of #190 out of 636 in its category (2023), placing it in the 70th percentile. Since its inception in 1922, MEDICINE has been a vital platform for researchers, professionals, and students to disseminate groundbreaking findings and advancements in the medical field. With the transition to open access in 2014, the journal ensures that valuable research is readily available to a global audience, fostering collaboration and innovation across diverse medical disciplines. Its current impact factor and influence in the miscellaneous medicine category (Q3) reflect its commitment to supporting rigorous peer-review processes and promoting scholarly excellence. Located in Philadelphia, PA, the journal covers a wide range of topics, making it a crucial resource for those dedicated to the betterment of healthcare and medical education.

Avicenna Journal of Phytomedicine, published by Mashhad University of Medical Sciences, is a premier Open Access journal dedicated to advancing the field of phytomedicine. Established in 2011, this journal aims to promote research on the therapeutic potentials of medicinal plants, integrating traditional knowledge with modern pharmacological insights. With an ISSN of 2228-7930 and an E-ISSN of 2228-7949, it has garnered significant attention in the research community, achieving a Q2 ranking in Complementary and Alternative Medicine and a Q3 ranking in Drug Discovery as of 2023. Its Scopus rankings affirm the journal's relevance, with the journal positioned at 37 out of 105 in its category, reflecting a 65th percentile. The Avicenna Journal of Phytomedicine serves as an invaluable resource for researchers, professionals, and students seeking to explore innovative botanical therapies, making it a notable platform for disseminating high-quality research in this burgeoning field.

The Journal of Ethnopharmacology, published by Elsevier Ireland Ltd, is a pivotal resource in the fields of Drug Discovery and Pharmacology, recognized as a Q1 journal in both categories as of 2023. With a rich history since its inception in 1979, this peer-reviewed journal provides a platform for rigorous research and innovative findings related to traditional medicinal practices and the therapeutic potential of natural products. The journal is ISSN 0378-8741 and E-ISSN 1872-7573, and it plays a vital role in advancing knowledge through its high-quality publications, which rank impressively at #35 out of 313 in Pharmacology and #19 out of 157 in Drug Discovery according to Scopus metrics. Although not open access, the journal aims to cater to a diverse audience of researchers, professionals, and students dedicated to exploring the intersection of ethnopharmacology and modern scientific inquiry. Its comprehensive scope encapsulates a multitude of studies spanning the globe, fostering a deeper understanding of how traditional practices can inform contemporary health solutions.

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY is a prestigious journal published by SPRINGER, focusing on the dynamic fields of pharmacology and toxicology. With an ISSN of 0028-1298 and an E-ISSN of 1432-1912, this esteemed publication has been a staple in the scientific community since its inception in 1969, continuing to wield influence with a convergence of research that reaches through 2024. Ranked in the Q2 category for both medicine and pharmacology, it stands at an impressive 111th out of 313 in the Scopus rankings for pharmacology, reflecting its significant impact in the field. Though not offering open access, the journal remains a vital resource for researchers, professionals, and students seeking to explore groundbreaking studies and advancements in pharmacological science. With its high standards and comprehensive coverage, NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY is essential reading for those dedicated to understanding the mechanisms of drug action and the complexities of therapeutic interventions.

Frontiers in Pharmacology, published by FRONTIERS MEDIA SA, stands as a leading open-access journal dedicated to advancing the field of pharmacology since its inception in 2010. With its ISSN 1663-9812, the journal is based in Switzerland and maintains a vital role in disseminating innovative research findings that span various disciplines within pharmacology, including pharmacokinetics, toxicology, and pharmacogenetics. In 2023, Frontiers in Pharmacology has achieved an impressive standing within the scientific community, being ranked in the Q1 category for both general and medical pharmacology, highlighting its critical contribution to the field with a Scopus ranking of #41 out of 272 in medical pharmacology and #76 out of 313 in pharmacology, toxicology, and pharmaceutics, placing it in the 75th and 85th percentiles, respectively. Researchers and practitioners benefit from its open-access model, which ensures widespread accessibility to groundbreaking research, fostering collaboration and innovation across the pharmaceutical sciences. With its commitment to excellence, Frontiers in Pharmacology serves as an essential resource for those looking to explore and contribute to the latest advancements in pharmacological research.

Welcome to the Iranian Journal of Pharmaceutical Research, a pioneering publication in the field of pharmacology, toxicology, and pharmaceutics, published by BRIEFLAND. Established in 2002, this journal has been a crucial platform for disseminating innovative research and scholarly articles, contributing significantly to the advancement of pharmaceutical sciences in Iran and beyond. With an impressive trajectory leading towards a convergence of knowledge by 2024, it proudly holds a Q3 ranking in Pharmacology (Medical) and a Q2 ranking in the broader realm of Pharmacology, Toxicology, and Pharmaceutics for 2023. The journal's influence is underscored by its Scopus rank of #25/80 in General Pharmacology, Toxicology, and Pharmaceutics, placing it within the 69th percentile, therefore appealing to researchers, professionals, and students alike. Although the journal operates under a non-open access model, it remains dedicated to providing high-quality research articles that explore the latest advancements in pharmaceutical sciences, making it an essential resource for anyone involved in this vibrant field of study.

Letters in Drug Design & Discovery is an esteemed journal dedicated to advancing the fields of Drug Discovery and Molecular Medicine. Published by Bentham Science Publishers, this journal offers a platform for the dissemination of innovative research and advanced methodologies, enhancing collaboration among researchers and professionals in pharmaceutical sciences. Despite its current Q4 ranking in Drug Discovery and Molecular Medicine and Q3 in Pharmaceutical Science for 2023, the journal is committed to improving its presence in the academic community by providing quality, peer-reviewed publications that cover various aspects of drug design and discovery, including novel therapeutic approaches and methodologies. With a focus on both foundational and cutting-edge research from around the globe, Letters in Drug Design & Discovery is pivotal for those seeking to stay abreast of developments in drug development and molecular research. Researchers are encouraged to submit their work, engage with the burgeoning field, and contribute to the ongoing dialogue driven by this journal, which spans the years from 2005 to 2024. While the journal does not currently offer open access, its contributions remain accessible to a wide range of academic and professional audiences.